|
 |
| home > epc > winter 2001 > the monoclonal anti-idiotype antibody aca 125 - a breakthrough for ovarian cancer |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Q About 1.5 per cent of the female population suffer from ovarian
carcinoma - a tumour disease with a high mortality rate - in the
course of their lifetime. It is the fourth most common cause of
death from cancer in women. So why is the prognosis of this
malignant disease so bad?
A Due to the difficulties in making an early diagnosis of ovarian carcinoma, more than 70 per cent of the patients are only diagnosed at advanced stages and almost 20 per cent are already at stage four by the time of diagnosis. Accordingly, the prognosis for these tumours is comparatively poor. Although the prognosis for all stages regarding five-year survival has meanwhile increased, the relative five-year survival rate with advanced tumours is essentially lower. The number of lost years of life adds up to a total of about 100,000 years within the Federal Republic of Germany alone.
Q What approach is taken to the therapy of ovarian carcinoma
depending on the severity, for example a favourable prognosis,
but also rapid progression of large tumour masses and visceral
metastases?
A The aim of primary treatment of ovarian carcinoma is to firstly attain a favourable starting position for further treatment. The prognosis of the disease heavily depends on the post-operative tumour remains from the initial surgical operation. Subsequent treatment by means of chemotherapy - which must be carried out after the operation - is clearly dependent on the result of the surgical operation. Response rates of between 70 and 80 per cent are attained here. However, a smaller number of patients progress relatively quickly into a relapse situation, even after optimal initial therapy that appears to be resistant to chemotherapy and incurable.
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
PAT and Quality by Design for Biopharmaceuticals
25-26 May 2010, London, UK
Pharma IQ is delighted to announce the inaugural PAT and quality by design for biopharmaceuticals, being held in London on the 25th-26th May 2010. With PAT and quality by design techniques now established within the small molecules field the focus is shifting to application within the biopharmaceuticals arena, with key regulatory bodies such as the FDA and EMEA actively getting involved I pilot case studies. This event will bring together professionals specifically tasked with implementing PAT and QbD tools and techniques specifically within the bioprocess and bioproduction area.
More info >> |
|
 |
News and Press Releases |
 |
Almac Launches New STEMS System to Transform Temperature Controlled Shipment Monitoring in Clinical Trials
Almac Clinical Services marked the start of 2010 with the official launch of a new state-of-the-art web-based, Shipping Temperature Electronic Monitoring System - stems. Unique to the pharmaceutical and biotech industries, this latest addition to the Almac services portfolio is set to revolutionise the management of temperature controlled shipments within the clinical trial industry.
More info >> |
|
|
